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s0010 1. GENERAL DESCRIPTION OF THE DISEASE
p0010 Human onchocerciasis, or river blindness, is a debilitating disease that is
endemic in 31 countries in sub-Saharan Africa, in three Latin American
countries (Brazil, Guatemala, and Venezuela) and in Yemen.1 The causative
agent, Onchocerca volvulus, is a filarial nematode (Order: Filariata, Family
Onchocercidae) that is transmitted by a black fly Simulium damnosum and other
related species. The disease occurs when embryonic nematodes (microfilariae)
migrate to eye tissues, causing keratitis and the formation of opacity on the
cornea and pupil that leads to blindness. Ocular onchocerciasis is the cause
of 4% of avoidable blindness cases (WHO data) in sub-Saharan Africa and
affects over 37 million people, while over 80 million Africans are at risk of
infection by this parasite. This disease affects some of the world’s most disad-
vantaged communities, 99% ofwhich are in remote, rural areas in sub-Saharan
Africa. Onchocerciasis is the second leading infectious cause of preventable
blindness. Furthermore, it causes an array of serious morbidities, including
intense itching, onchocercal skin disease, musculoskeletal pain and general
malaise, weight loss, and elephantiasis of the genital.2 It is further suspected
to be a cause of epilepsy,3 and reports of onchocerciasis-associated dwarfism
in Uganda, presumably resulting from microfilarial damage to the pituitary,
have been described.4 Beyond health issues, onchocerciasis leads to grave
social and economic consequences that exacerbate poverty and hinder overall
development.5 Patients also experience social stigmatization besides decreased
body mass index and work productivity. Onchocerciasis is responsible for
0.962 million disability-adjusted life years (DALYs) annually, while trouble-
some itching accounts for 40% of DALYs attributable to onchocerciasis.6
p0015 Great progress has been made in the efforts to control onchocerciasis in
the last 3 decades. This has occurred both in Africa and the Americas
thanks to concerted efforts by the Onchocerciasis Control Programme in
West Africa (OCP), the African Programme for Onchocerciasis Control
(APOC), and the Onchocerciasis Elimination Programme in the Americas
(OEPA). The WHO has verified the remarkable successes obtained by
OEPA with the elimination of the transmission of the parasite in Columbia,
Ecuador, and Mexico in 2013, 2014, and 2015, respectively, and declared
them free of the disease.7 These relevant successes suggest that the disease
has been or can be eliminated, even with currently available tools, in most
areas if the right strategy is used and if the required financial input and
support is given. There are still challenges to face and these open up the need
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for research to: (a) find the optimum diagnostic tool, especially one that is
sufficiently sensitive and specific for Onchocerca so as to be used to assess
whether onchocercal infection has been eliminated in a locality;
(b) discover an acceptable macrofilaricide that can either kill or sterilize
the adult worm and therefore help shorten the treatment period; (c) find
the best approach for the sustainability of the drug distribution program,
which is essential to maintaining pressure on the parasite; and (d) perform
research to discover, as early as possible, any resistance to the drug currently
in use and the best way to overcome it.
s0015 1.1 The Parasite and Its Life Cycle
p0020 The nematode,O. volvulus, is transmitted by small Simulium spp. black flies,
with mankind its only definitively known reservoir (Fig. 1). An infected
black fly deposits one or more O. volvulus larvae into the host when it takes
a blood meal. These larvae develop into mature adult worms in about a year.
They commonly aggregate into fibrous nodules that lie under the skin and
usually over bony prominences. The adult female has a size of 30–80 cm and
a mean life span of 12–15 years with a reproductive life span of about
9–11 years.8 When fertilized by a male worm, she releases millions of
embryos called microfilariae, which themselves live for about 2 years. The
microfilariae migrate from the nodules, invading the skin, eyes, and some
organs from where they are taken up with the bite of a vector. The micro-
filariae develop into infective larvae in the black fly upon migrating from the
black fly’s midgut, through the hemocoel, to the thoracic muscles. Once
there, the microfilariae develop into first-stage larvae (L1) and subsequently
into third-stage infective larvae (L3). The third-stage infective larvae migrate
to the black fly’s proboscis and can infect another human when the fly takes a
blood meal, thus completing the life cycle of the parasite. Development of
the microfilariae from the L1 larvae through L3 infective larvae spans a period
of 10–12 days.
s0020 1.2 Clinical Presentation
p0025 The clinical manifestation of onchocerciasis occurs 1–3 years after infection.
People with severe infections have millions of microfilariae in their skin, eyes,
lymph nodes, and other organs. In addition to severe itching and possibly
secondary infection, a victim often experiences severe dermatitis involving
hypo- or hyperpigmentation, and the thickening and wrinkling of the skin.
These latter symptom often occurs together with scaling or “lizard skin.”9
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When the microfilariae migrate from the skin to enter the eyes, they cause,
whether dead or alive, ocular morbidity and visual impairment, including
permanent blindness.10 Loss of vision is caused by acute and chronic ocular
diseases of both the anterior segment (sclerosing keratitis and iridocyclitis)
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Fig. 1f0010 Onchocerca volvulus life circle. During a blood meal, an infected black fly (genus
Simulium) introduces third-stage filarial larvae onto the skin of the human host, where
they penetrate into the bite wound ➊. In subcutaneous tissues, the larvae ➋ develop
into adult filariae, which commonly reside in nodules in subcutaneous connective tis-
sues ➌. Adults can live in the nodules for approximately 15 years. Some nodules may
contain numerous male and female worms. Females measure 33–50 cm in length and
270–400 μm in diameter, while males measure 19–42 mm by 130–210 μm. In the sub-
cutaneous nodules, the female worms are capable of producing microfilariae for
approximately 9 years. The microfilariae, measuring 220–360 μm by 5–9 μm and
unsheathed, have a life span that can reach 2 years. They are occasionally found in
peripheral blood, urine, and sputum, but are typically found in the skin and lymphatics
of connective tissues ➍. A black fly ingests the microfilariae during a blood meal ➎.
After ingestion, the microfilariae migrate from the black fly’s midgut through the
hemocoel to the thoracic muscles ➏. Once there, the microfilariae develop into first-
stage larvae ➐ and subsequently into third-stage infective larvae ➑. The third-stage
infective larvae migrate to the black fly’s proboscis ➒ and can infect another human
when the fly takes a blood meal ➊.Q1 Reproduced directly from https://www.cdc.gov/
dpdx/onchocerciasis/index.html.
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and posterior segments (optic nerve disease, optic atrophy, and
choroidoretinitis) of the eye. Blindness that appears later in the disease is
the most serious consequence of onchocerciasis. The severity of onchocercal
ocular disease varies considerably from one geographical zone to the next.
Blindness from onchocerciasis is extensive in hyperendemic populations in
the West African savannah, while virtually no, or little, blindness is found in
forest villages with a comparable intensity of infection.
p0030 The inefficacy of ivermectin against adult worms means that early diag-
nosis11 and an early start to treatment are essential. However, as onchocer-
ciasis is present in underdeveloped countries, important therapy-related
decisions must often be made without the benefit of a complete informative
scenario. This is what happened to a number of treatment and prevention
campaigns that were suspended in some communities after ivermectin
was found to harm patients who were also infected with another parasite,
commonly known as Loa loa, or the African eye worm. L. loa is able to cause
blindness, quite like O. volvulus, and is transmitted via deerflies found in
the rainforests of West and Central Africa. Administering ivermectin to
patients with high L. loa levels (exceeding 30,000 per milliliter of blood)
can potentially lead to severe or fatal brain damage. In order to quantify
the prevalence of L. loa parasites in a patient and determine their eligibility
for ivermectin treatment, laboratory technicians traditionally count them
manually in blood samples, a technique that is not conducive to use in
the field or in mass treatment campaigns. This problem has been cleverly
solved by a new iPhone app named CellScope Loa, designed by a group of
undergraduate students at UC Berkeley and supported by Melinda & Bill
Gates Foundation.12
s0025 2. DRUGS AND DRUG COMBINATIONS IN CLINICAL OR
PRECLINICAL EVALUATIONS
p0035 In accordance with current mass drug administration (MDA) programs,
the mainstay chemotherapy against onchocerciasis are combinations of iver-
mectin (IVM), diethylcarbamazine (DEC) with albendazole (ALB) for lym-
phatic filariasis and IVM for onchocerciasis.13 The activity of these drugs is
seen in their significant ability to kill microfilariae and late-stage embryos in
adult female worms. However, these therapies have little effect on the adult
worms themselves, and the aim of MDA programs is therefore to break
transmission.1 A thorough description of each of the approved treatments
has been provided in the following texts.
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s0030 2.1 Diethylcarbamazine (DEC)
p0040 Diethylcarbamazine (N,N-diethyl-4-methyl-1-piperazinecarboxamide, DEC,
Fig. 2) was proven to be effective against filarial parasites in the late 1940s.14
p0045 Although it was recognized relatively early in its life that DEC can cause
adverse reactions in individuals infected with O. volvulus, it was the rec-
ommended first-line treatment for onchocerciasis for about 40 years until bet-
ter alternatives, such as ivermectin, were introduced.15 A treatment course of
oral DEC was used for both individual and community treatment,16 as it pre-
sents little intrinsic toxicity. However, large doses may lead to anorexia,
nausea, vomiting, headaches, and drowsiness. In onchocerciasis patients how-
ever, systemic reactions, which can be attributed to the death of microfilariae
and were first described by Mazzotti15 are observed. The systemic reaction
may occur in two phases. In the “primary” phase, which is a constant feature,
commences within 24 h and manifests itself as a variable combination of
increased itching, a rash, headaches, muscle aches, joint pains, gland tender-
ness, pain and swelling, hypotension, dizziness, tachycardia, fever, and acute
respiratory distress. Reaction severity is related to the number of microfilariae
killed. A “secondary” phasemay occur 2–6 days after the initiation of therapy. It
commonly presents itself as severe, symmetrical acute polyarthritis predomi-
nantly involving the knees, ankles, wrists, the interphalangeal joints, and the
shoulders. It is usually accompanied by a recrudescence of fever. Effusions
develop, commonly in the knee joints, in which microfilaria O. volvulus
can be found. Ocular reactions are common in patients with many micro-
filariae in the eye. These include itching, epiphora, photophobia, injection
of the conjunctiva, lid swelling (which may completely shut the eye), limbitis,
and acute iridocyclitis.17 The exact mechanism of DEC action is yet to be
elucidated, but is known to involve host components, including the
arachidonic acid pathway. Some studies have suggested that DEC has an indi-
rect, host-mediated mode of action as well as antiinflammatory effects.18 Else-
where, DEC has been shown to inhibit the cyclooxygenase and lipoxygenase
pathways in parasites, resulting in microfilaria death, and to result in a sharp
decline in microfilaria loads and an estimated adulticidal effect of 40% when
administered to infected subjects.19 Moreover, some studies have suggested
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Fig. 2f0015 Diethylcarbamazine (N,N-diethyl-4-methyl-1-piperazinecarboxamide; DEC).
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that the drug inhibits the activation of nuclear transcription factor kappa
B (NF-κB), a key regulator of proinflammatory genes, such as TNF-α and
IL-1β, as well as inducible nitric oxide synthase and cyclooxygenase 2.20 In
addition, DEC alters the host arachidonic acid and nitric oxidemetabolic path-
ways, resulting in the immobilization and sequestration of these parasites via a
yet-to-be-elucidated pathway. However, due to its severe adverse effects,
DEC is not recommended forMDAprograms in onchocerciasis endemic areas
where it may induce local inflammation in subjects with ocular microfilariae.
s0035 2.2 Ivermectin
p0050 The antiparasitic drug ivermectin (IVM) (Fig. 3) was initially approved in
humans in 1987 to orally treat onchocerciasis. Since 1987, theMectizan Dona-
tion Program has approved 1.4 billion treatments for the control and elimination
of onchocerciasis, and 1.2 billion treatments (administered with albendazole,
donated by GlaxoSmithKline) for the control and elimination of lymphatic
filariasis (http://www.mectizan.org/resources/2014-annual-highlights). One
drawback was that ivermectin does not kill adult worms, which would resume
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Fig. 3f0020 Compounds from the avermectin family. Some AVM family members are shown
in the picture. All of them are characterized by a 16-carbon macrocyclic lactone core
with a bisoleandrisyloxy substituent at C13.
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microfilariae production after about 6 months, meaning that around six to eight
repeated doses, at 6-month intervals, are thus necessary. Nonetheless, no drug
came close to ivermectin’s safety and efficacy for river blindness. Ivermectin
does not kill adult O. volvulus, but a single oral dose (150 mg/kg) given
annually suppressesmicrofilarial production and prevents disease progression.21
Ivermectin belongs to the avermectins (AVM), which is a group of 16-
membered macrocycliclactone compounds discovered in 1967 by the Nobel
Prize winner Satoshi Omura of the Japanese Kitasato Institute. From fermenta-
tion broths of actinomycete cultures and the fungus Streptomyces avermitilis, he
collected extracts containing macrocyclic lactones, which are responsible for
antihelminthic activity, along with ivermectin B1, a component that presents
the leading activity.22 AVM family members include selamectin, abamectin,
moxidectin, ivermectin (Fig. 3) among others, all of which differ from the anti-
bacterial and antifungal 16-membered macrocyclic lactones in that they bear a
bisoleandrosyloxy substituent at C13.23
p0055 Ivermectin is the most commonly employed of the AVM group, as it is a
more potent and safer semisynthetic mixture of two AVMs, 22,23-
dihydroavermectin-B1a and dihydroavermectin-B1b, at a ratio of 4:1,
respectively (Fig. 4).24
p0060 Ivermectins potentiate neurotransmission by disrupting glutamate-gated
chloride channels, and they also have minor effects on γ-aminobutyric acid
(GABA) receptors. They disrupt neurotransmission in nerve and muscle
cells, causing neuronal membrane hyperpolarization and inducing paralysis
in the somatic muscles, particularly the pharyngeal pump, which kills the
parasites. GABA-related channels are commonplace throughout nematodes
and insects, whereas GABA receptors and neurons are restricted to the
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Fig. 4f0025 AVMs. 22,23-Dihydroavermectin-B1a and dihydroavermectin-B1b structures.
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central nervous system inmammals. Ivermectin is therefore very safe for ver-
tebrates, as it cannot cross the blood–brain barrier.23
p0065 Attempts have beenmade to improve ivermectin efficacy in recent years.
In The Lancet, Nicholas Opoku et al. have presented the results of a multi-
center trial, including about 1500 participants that compared the effect over
18 months of single doses of ivermectin and moxidectin on O. volvulus
microfilariae.25
p0070 Skin microfilarial loads (i.e., parasite transmission) are lower after
moxidectin treatment than after ivermectin treatment. Moxidectin (Fig. 3)
would therefore be expected to reduce parasite transmission between treat-
ment rounds more effectively than ivermectin and thus accelerate progress
toward disease elimination. Programmatically speaking, moxidectin has two
main advantages: annual treatment could affect onchocerciasis transmission
to a similar extent to that of biannual ivermectin treatment, while the effect
on transmission is not as dependent on the relationship between treatment
time and peak transmission season as that of ivermectin is.26
s0040 2.3 Benzimidazole Drugs
p0075 The most appealing benzimidazole drug with regard to combating filarial
parasites is flubendazole (Fig. 5),27 which is a benzimidazole approved for
the treatment of gastrointestinal nematodes in humans that has been shown
to be active also against the pathogens that cause onchocerciasis,28 and to have
essentially 100% efficacy as a macrofilaricide when administered parenter-
ally.27 However, parenteral administration is a concern as the subcutaneous
administration of flubendazole causes intolerable pain, while intramuscular
injections induce inflammation.28 Furthermore, there is a grave shortage of
qualified healthcare workers that can safely administer injections in developing
countries.29 Improper sterilization practices and a lack of injection equipment
supplies have been reported in various African countries by the WHO.30
The promise shown by flubendazole as a macrofilaricide and the opportunities
that novel drug formulation techniques offer for an oral formulationwith high
bioavailability have been indicated by Mackenzie and Geary.27 A partnership
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Fig. 5f0030 The structure of flubendazole (left) and albendazole (right).
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between Michigan State University in the United States, McGill University
in Canada, and the not-for-profit organization “Drugs for Neglected Diseases
Initiative” (DNDi) was formed in 2011 to develop a suitable oral formulation
of flubendazole and conduct the relevant pharmacodynamic, pharmacoki-
netic, and toxicology studies. The work of the partnership was supported
by a grant from the BMGF and Johnson&Johnson joined the initiative in
2012. DNDi has since completed its involvement in the project and has
transferred all data to Johnson&Johnson. New oral formulations, one that
makes use of an aqueous hydroxypropyl-b-cyclodextrin (CD) suspension
and another using an aqueous carboxymethyl cellulose suspension, have
been developed, as has a Tween 80-based formulation (TWEEN).31 The oral
bioavailability enhancement of flubendazole has recently been obtained via
the development of nanofibrous solid dosage forms.32 An oral formulation
with higher systemic bioavailability than the formulations used for treatment
of intestinal nematodes requires additional preclinical toxicology and
pharmacotoxicity studies in view of the fact that flubendazole interferes with
microtubules and may thus present reproductive toxicity.27 Benzimidazoles
work by interfering with the equilibrium between tubulin subunits, tubulin,
and microtubules. Unsurprisingly, benzimidazoles can affect host tubulin as
well as that of the parasites are typically positive in mammalian cell cytotoxicity
assays and cause chromosomal nondisjunction during mitosis.33 However,
benzimidazole anthelmintics show a differential preference for binding to
nematode tubulin over mammalian tubulin,34 which is an important factor
in the development of a drug against nematodes in mammals. The results of
the first preclinical toxicology studies conducted have been published35 and
show that, when flubendazole was administered orally in a bioavailable formu-
lation, it interfered with normal rat embryonic development in a dose-
dependent manner, which is deeply and strictly related to the amount of drug
in the maternal plasma that consequently reaches the embryo. This fact does
not impact negatively on the possibility of proceeding with the development
of a new flubendazole formulation which is highly bioavailable and highly
effective as a macrofilaricide, as the benefit of developing this drug in terms
of control and eradication of filariasis overcomes the disadvantages of having
a drug with a potential risk in pregnancy. In fact, the potential new drug
could be used under controlled administration for the treatment of individual
patients in order to avoid the risk of inadvertently treating pregnant women.
However, the development of flubendazole by Johnson&Johnson was discon-
tinued due to nonclinical toxicology data (Fig. 5).36
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s0045 2.4 Doxycycline
p0080 The search for new drugs that can enhance elimination by permanently ster-
ilizing and killing the adult worms has identified a 4–6-week course of doxy-
cycline (Fig. 6), which is a slow-killing drug due to its indirect mode of action
of killing endosymbiotic bacteria.37 Doxycycline is the first and, so far, only
macrofilaricidal drug against onchocerciasis. More importantly, Mand et al.38
have observed that doxycycline can be effective in patients without active
infection since it demonstrated exceptional antiproliferative activity and
led to improved pathology conditions. This suggests that this drug can be
used as an effective tool for individual drug treatment in filarial endemic
areas.39 While doxycycline application in field studies has shown interesting
macrofilaricidal effects when compared with conventional antifilarial drugs,40
its universal application has been hampered due to contraindications among
pregnant women and children under 9 years of age. This fact, coupled with
current reports of IVM resistance in some endemic communities,23 high-
lights the need for the development of new and effective antifilarial drugs
and/or vaccines if the goal of eliminating Lymphatic filariasis (LF) and oncho-
cerciasis is to be achieved by 2020 and 2025, respectively.19 Long treatment
length and contraindications in children and pregnancy are obstacles to
implementing doxycycline as a public health strategy.41 Doxycycline elicits
a gradual, yet sustained, reduction in microfilaridermia, not because it kills
O. volvulus microfilariae directly, but because the microfilarial population
is not replenished by (sterilized) female worms, with skin microfilariae
declining through natural attrition. Adult worms suffer a similar “slow-kill”
effect. An increased abundance of dead O. volvulus worms is observed
approximately 2 years after the start of doxycycline therapy.39
s0050 2.5 Rifampicin
p0085 Recent studies have also shown that rifampicin exhibits (Fig. 6)
macrofilaricidal activity.42 Clinically relevant dose elevations of rifampicin,
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Fig. 6f0035 The doxycycline (left) and rifampicin (right) structures.
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which have recently been determined as safe in humans, can be administered
as short courses to filariasis target populations with the potential to reduce
anti-Wolbachia curative therapy times to between 1 and 2 weeks.42
s0055 2.6 Emodepside
p0090 Emodepside (Fig. 7) is a semisynthetic compound whose precursor is a
metabolite of the fungus Mycelia sterile. Clinical development is underway
in the United Kingdom and preclinical research is underway in Germany.
p0095 Emodepside, which has been approved in combination with praziquantel
for veterinary use, has efficacy in animal filarial models.13 The DNDi has
initiated a phase 1 study of its safety, tolerability, and pharmacokinetics in
healthy volunteers (NCT02661178). Studies inO. volvulus and Loa-infected
individuals are planned for 2018. Emerging efficacy and safety profiles will
determine whether emodepside development will continue and whether it
will be developed for Community Direct Treatment/MDA or Test and
Treat strategies.
s0060 2.7 Combination Therapy
p0100 The unique activities of each of the above-mentioned drugs have led to
them being used in specific combination therapies endemic regions.19
Recent studies,43 have shown that a single-dose combination therapy with
three currently approved antifilarial drugs (IDA as combination of Ivermec-
tin, Diethylcarbamazine, and Albendazole)44 is superior to current regimens
used in Lymphatic filariasis elimination programs. Although it has not yet
been tested, IDA may also be useful for treating onchocerciasis. Additional
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Fig. 7f0040 The emodepside structure.
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research will be needed to test whether it is safe and effective for treating
onchocerciasis, first in individuals and later in endemic populations both
with and without coendemic LF. IDA is likely to be more effective
for the clearance and suppression of microfilariae than ivermectin alone.
Compared to drugs that have not yet been tested in humans, IDA provides
a potential fast-track and low-cost option that could accelerate the
elimination of LF and onchocerciasis in Africa.43 The risk of general and
irreversible ocular diethylcarbamazine-related secondary adverse effects in
O. volvulus-infected individuals with high microfilaridermia requires that
a low microfilariae burden is confirmed in each individual before IDA treat-
ment. A TNT strategy that uses skin snips to quantify microfilaridermia
and carefully examines the ocular anterior and posterior segments would
be able to exclude individuals at risk of diethylcarbamazine-related SAEs
from IDA treatment. Moreover, the development of drug resistance or
the induction of severe adverse events following treatment, or contraindi-
cations for DEC in areas endemic for onchocerciasis, drives the need for
the identification and development of alternative therapeutics, along with
sensitive diagnostic tools to assess for efficacy of these alternative treatment
strategies.45
s0065 3. RECENT ADVANCES BEYOND IVERMECTIN
p0105 Although the lack of a safe and effective drug against the adult worm
and the emergence of animal parasite strains that are resistant to ivermectin
have put many at risk of the devastating effects of onchocerciasis, the Drug
Design scenario of studies directed toward alternative therapeutic treatments
has been very poor over the past 20 years. Unfortunately, this means that
onchocerciasis really falls within the definition of “neglected diseases.” The
following sections present and comment upon the results of a bibliography
search on events in the field over the past 20 years. In Section 3.3, the
authors also describe the scenario of possible new targets for O. volvulus,
which are not currently being investigated in terms of Drug Design, but
as sources of future possibilities.
s0070 3.1 Searching for Chemodiversity within Natural Sources
p0110 Organic compounds obtained frommother nature still have extensively uses
in the treatment of many diseases.46 These approved substances and other
natural products undergoing clinical trials represent very wide chemical
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diversity and continue to demonstrate the importance of compounds from
natural sources in modern drug discovery.47 Traditional medicines make use
of natural products and are still of great importance all around the world, in
particular where neglected diseases are involved. Such forms of medicine
have been practiced for hundreds or even thousands of years and are a valu-
able repository of human knowledge and possibly sources of future drugs.48
In this sense, Metuge et al.49 investigated the acclaimed anti-onchocerca activ-
ity of the roots/rhizomes of Cyperus articulatus in the traditional treatment of
onchocerciasis in NorthWestern Cameroon with the purpose of identifying
potential filaricidal lead compounds. The essential oil from the roots/rhi-
zomes ofC. articulatus was found to be active againstO. ochengimicrofilariae
and adult worms in a dose-dependent manner in vitro. Although no further
steps have yet been reported, these results may prove to be a source of new
antifilarial compounds that support the traditional use of C. articulatus in the
treatment of human onchocerciasis.
p0115 Following a similar approach, Samje et al.50 screened the chromato-
graphic fractions of crude extracts fromCraterispermum laurinum andMorinda
lucida, plants which have traditionally been used to manage O. ochengi,
against the disease in vitro.Of the 18 extracts screened, themethanolic extracts
of the leaves of both plants recorded the highest activities against both the
microfilariae and adult worms. The most active chromatographic fraction
was obtained from M. lucida and had an IC50 of 7.8 and 15.63 μg/mL on
microfilariae and adult worms, respectively. A phytochemical analysis of
the most active fractions revealed the presence of sterols, alkaloids, triterpenes,
saponins, and flavonoids, which are sources of potential future chemotypes.
Acacia nilotica fruits with high tannin contents are used in the northern parts
of Cameroon as antifilarial remedies by traditional healers.
p0120 A further two studies have investigated traditional Cameroonianmedicine.
In the first, Vildina et al.51 assayed the hydro-alcoholic fruit extract of plants
traditionally used and one of the main constituents in its most active fractions,
(+)-catechin-3-O-gallate, together with four related proanthocyanidins, for
their potential in vitro anthelmintic properties against the free-living model
organism Caenorhabditis elegans and the filarial cattle parasite O. ochengi and
found activities in the 1.2–350 μg/mL LC50 range. These results are in good
accordance with the use of A. nilotica against nematode infections by tradi-
tional healers, herdsmen, and pastoralists in Cameroon.
p0125 In the second study, Nyasse et al.52 investigated a number of Camer-
oonian medicinal plants that are known to be active against O. volvulus
and Onchocerca gutturosa. They screened three compounds, polycarpol,
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polyveoline, and 3-O-acetyl aleuritolic acid (Fig. 8) isolated from Dis-
coglypremna caloneura (Euphorbiaceae), Polyalthia suaveolens (Annonaceae),
and D. caloneura (Euphorbiaceae), respectively. Only polycarpol and
3-O-acetyl aleuritolic acid exhibited significant inhibitory activity on
the vitality of adult male O. gutturosa worms and Amocarzine was used
as positive control compound.
s0075 3.2 The Repositioning of Closantel: Targeting OvCHT1
Chitinase
p0130 Besides the studies of Mainsah et al.,53 which reported in 2016, the activity of
Cu(II) isoniazid-derived Schiff bases (Fig. 9) against both micro- and
macrofilaria, with IC50 values of 5 and 10 μg/mL, respectively, the only other
drug design study presenting an appreciable level of complexity, in the last
decade, was the repositioning of closantel (Fig. 10), a veterinary anthelmintic
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Fig. 8f0045 3-O-Acetyl aleuritolic acid.
Fig. 9f0050 Schiff bases designed by Manisah et al.
Fig. 10f0055 The closantel structure (the three rings have been indicated referring to
Gloeckner et al.55).
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with known proton ionophore activity, that was performed by the Janda
group at the Scripps Institute in La Jolla (USA)55 (see Figs. 10 and 11).
p0135 Neglected diseases have not been the focus of big pharmaceutical company
research because the difficulties in recouping research and development
costs do not make them profitable over the long term. However, pharma-
ceutical companies are recently beginning to view rare and neglected dis-
eases as an opportunity to bring in more revenue as well as to improve
public relations.54 One strategy that can solve the problem is combining a
hastening of the drug discovery of ND and the benefits for pharmaceutical
companies, thus expanding their market. The strategy of examining new
uses for existing approved drugs, so called “drug repositioning” or “drug
repurposing,”55 works in this direction. One of the benefits of repositioning
a drug to a different purpose is the availability of materials and data that can
accelerate the entrance of the new molecular entity to the market.
p0140 In 2001, Wu et al.56 reported the presence of a chitinase, which belongs
to the family 18 glycosyl hydrolases and were designated OvCHT1, in
O. volvulus. Chitin is one of the most widespread amino polysaccharides
in nature and constitutes a major structural component of the microfilarial
sheath and eggshells of parasitic nematodes. Two enzymes, chitin synthases
Comp. by: S.Rajaram Stage: Revises1 Chapter No.: 1 Title Name: ARMC
Date:24/9/18 Time:07:47:30 Page Number: 16
Fig. 11f0060 Simplification of the dual activity profile closantel structure how described by
Garner et al.59 The 3,5-diiodosalicilate analog 3f retained the OvCHT1 chitinase activity
profile loosing the proton ionophore profile characteristic of closantel. The opposite
behavior was found for 3w.
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and chitinases, regulate the dynamic biosynthesis and degradation of chitin,
which is a crucial process for the growth and development of these organ-
isms. In theO. volvulus parasite, OvCHT1 is expressed solely in the infective
L3 larvae and is stored within the granules of the cells of the esophageal
glands until postinfective development, after which it is secreted and found
mostly in the cuticle. Its exact mechanism of action is still under investiga-
tion although it has been hypothesized to play roles in the infectivity of the
parasite, aiding its escape from the vector and/or participating in early post-
infective migration and/or development. Its involvement is such in these
processes, which are so critical to the life cycle of the parasite, that OvCHT1
was made a relevant therapeutic target in O. volvulus. In 2003, the same
group reported OvCHT1 as an antigen that strongly induces both humoral
and cellular immune responses in humans.57 Following such discoveries on
OvCH1 roles, Gloeckner et al.55 conducted a screening against OvCHT1
using the Johns Hopkins Clinical Compound Library, which that contains over
1500 existing drugs. Closantel, already approved for veterinary uses, was
identified as a potent and specific inhibitor of this filarial chitinase, with
an IC50 of 1.6 μM. Additional experiments showed that the mode of inhi-
bition for this compound is competitive with a Ki of 468 nM. This com-
pound was also found to be highly specific for filarial family 18 chitinases,
compared to those from protozoans and the human chitinase, human
chitotriosidase. Notably, closantel was also found to completely inhibit
the molting of O. volvulus infective L3 stage larvae.
p0145 In 2011, Segura-Cabrera et al.58 speculated as to closantel’s binding
mode to OvCHT1 using in silico methodologies. In the absence of a crys-
tallographic structure for OvCHT1, the authors developed a homology
model of OvCHT1 using the currently available X-ray structures of human
chitinases as templates. Using molecular dynamics simulations and free-
energy calculations, they identified the structural features and properties that
were responsible for differences in the computationally predicted closantel
binding modes. In particular, the authors suggested that the closantel 3,5-
diiodosalicylic acid moiety is fundamental for anchoring the molecule to
the OvCHT1 biding site, and that it thus plays an important role in closantel
specificity (Fig. 10).
p0150 Molting is a key developmental process for parasitic nematodes, and
interference with molting is fatal to parasite development. In O. volvulus,
the L3 to L4 larval molt is of critical significance in the nematode lifecycle,
as it represents the transitional stage between the vector and the host and is
necessary for active infection of and further development within the human
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host. Following the discovery of closantel’s OvCHT1 inhibition properties,
in 2011, Garner et al.59 thoroughly investigated the role of the 3,5-
diiodosalicylic moiety in closantel’s activity toward OvCHT1. As closantel’s
anthelmintic activity as a veterinary drug is thought to be due to its role as
a proton ionophore, the authors dedicated affords to discern the impact of chi-
tinase inhibition and mitochondrial uncoupling in the molting of O. volvulus
L3 larvae. A small series of simplified analogs were synthesized from closantel,
and the authors were able to associate the OvCHT1 activity profile to the
presence of a 3,5-diiodosalicilamide moiety in the closantel structure. How-
ever, when in the salicilamide moiety the iodine substituents were replaced
with isopropyl groups, OvCHT1 activity was lost and a potent proton ion-
ophore was found.
p0155 These studies demonstrated that both protonionophore and chitinase
inhibition activities are necessary to affect the molting of O. volvulus L3 lar-
vae. Starting from these results, Gooyit et al.60a focused on scaffold expan-
sion of the aniline moiety of closantel designing a series of analogs.
p0160 In fact, they identified potent bifunctional analogs as well as compounds
that were just OvCHT1 inhibitors. These bifunctional compounds were
also found to readily bioaccumulate in the model nematode C. elegans at
concentrations up to>75% of the initial dose. The results clearly established
the significance of each biochemical role in modulating the O. volvulus
L3-to-L4 molt and proved that synergistic activities provided a formidable
impact on the molting process. In these series of closantel structure modi-
fications, beside the fact the 3,5-diiodosalicylate moiety is key to closantel’s
binding specificity by anchoring it within the OvCHT1 active site, the phe-
nolic hydroxyl group was not considered crucial for activity and its removal
did not affect activity, as the activity of 3i (Fig. 12) prove. This suggests that
the diidosalicylate moiety most likely interacts with nonspecific hydropho-
bic contacts within the active site and is therefore amenable to fragment
replacement and manipulation. The “scaffold hopping” strategy was applied,
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Fig. 12f0065 Compound 3i by Goovit et al. a potent OvCHT1 inhibitor in the nanomolar range
(Fig. 13).
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on two occasions, to the 3,5-diiodosalycilic moiety in order to explore the
biological space of OvCHT1 and generate novel molecular frameworks
with improved potency. In the first case, Gooyit et al.60b simplified the
structure of closantel by replacing the diiodosalicylate moiety, initially, with
a phenyl group bridged to a phenoxyphenyl system via an amide bond, and
then later with more complex groups (Fig. 13).
p0165 In the second case, applying an effective and consolidated bioisosteric
strategy to mimic the acidic moiety by hydrozyazole scaffolds,61a–h Pippione
et al.62 replaced the 3,5-diiodosalycilic core with a hydroxytriazole scaffold.
During the subsequent fine tuningmodulation of the hydroxytriazole scaffold,
the role of three possible substitutions on the N-triazole ring was determined.
The fact that the phenolic group in Gooyit’s analogs can be successfully
alkylated without affecting chitinase inhibition meant that O-alkylated
triazole analogs were also considered with the aim to explore the chemical
space around the triazole ring.63 These studies found that the presence of
either N(b) or N(c) alkyl substituents was beneficial to potency according
to the size of the alkyl substituent. A combination of these facts, together with
the presence of a benzyl substituent on the hydroxyl group, afforded sub-
micromolar range compounds. In Fig. 14 is shown the derivative 27, one
of themost potent compound the series based on the hydroxytriazole scaffold.
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Fig. 13f0070 Lowest energy pose of compound 3a from Gooyit et al.,61 docked into OvCHT1
(IC50 0.840.01) using the program AutoDock Vina. Color scheme: oxygens in red, nitro-
gens in blue, carbons in yellow (compound 3a) or gray (OvCHT1).
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p0170 In 2015, continued efforts to discover OvCHT1 inhibitors led Gooyit
et al.,60c to identify the β-carboline alkaloid scaffolding as a chitinase inhib-
itor that is capable of penetrating the worm cuticle. In particular, the authors
presented the rich polypharmacology of the β-carboline class of compounds
as an approach to abrogate the parasite molting and thus the infection in a
human host.
s0080 3.3 Studies on New Therapeutic O. volvus Targets
p0175 Although only a few new chemical entities and drug design programs have
been published on onchocerciasis over the last 20 years, a variety of biolog-
ical targets have been suggested for onchocerciasis therapy. The high-quality
genome assembly of O. volvulus was recently generated64 identifying
enzymes that are likely to be essential forO. volvulus viability as well as gen-
erating a list of proteins that could be targeted by repurposed drugs, provid-
ing starting points for antionchocerciasis drug development. These studies
might be an interesting starting point for future drug design opportunities.
A brief introduction to the most interesting of these can be found below.
s0085 3.3.1 Glutathione S-Transferase (GST)
p0180 Adult worm parasites survive an immune response that is directed against
them by a variety of mechanisms in their potential 15 years of development
in a human host. It has been proposed that glutathione S-transferase (GST)
enzymes may contribute to the persistence mechanisms that can aid
the parasite’s survival. Glutathione S-transferases are multifunctional
proteins that protect a cell from damage from toxic exogenous and endog-
enous compounds by catalyzing their conjugation to reduced glutathione.
Comp. by: S.Rajaram Stage: Revises1 Chapter No.: 1 Title Name: ARMC
Date:24/9/18 Time:07:47:31 Page Number: 20
Fig. 14f0075 In Pippione et al.62 approach, the hydroxytriazole scaffold was used to success-
fully replace the 3,5-diiodosalycilic core.
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They regulate the oxidative stress response, drug resistance, and modula-
tion of host immune defense mechanisms. Moreover, they also serve as
binding proteins for a range of organic substances such as the cytotoxic
products of lipid peroxidation, including lipid hydroperoxides and
reactive carbonyls. Such compounds would cause membrane damage in
the absence of GSTs. Structure-based drug discovery efforts against
O. volvulus have been focused on GSTs as they have been postulated to
protect the parasite against host-mediated lipid peroxidation of the mem-
brane.65 Three different O. volvulus GST enzymes have been identified to
date.66 Ov-GST1 is a prostaglandin D synthase, a glycoprotein which pos-
sesses a signal peptide that is cleaved off during the process of maturation.
Ov-GST1 was found in the media surrounding adult worms maintained in
culture, indicating that this enzyme is released from the worm in vitro. It
potentially participates in the modulation of immune responses by contrib-
uting to the production of parasite-derived prostanoids and restraining the
host’s effector responses, thus making it a potential target for chemother-
apy and vaccine development. The glutathione S-transferase, Ov-GST2,
shows significant and unusual differences in sequence and overall structure
when compared with other counterparts, particularly those of the human
host. This is especially true of helix α-2, an important region for substrate
recognition. It has been proposed that the principal role of cytosolic
Ov-GST2 is either to neutralize peroxidase activity or to passively bind
the cytotoxic lipid peroxidase products that arise from the immune-initiated
attack on parasitic membranes via glutathione (GSH) conjugation. A third
GST,Ov-GST3 plays a protective role against intracellular and environmental
oxygen species,67 and can be observed in the egg shell of the worm at themor-
ula stage of embryo formation unlike Ov-GST1, thus indicating its extremely
defined, stage-specific expression for a short transient period only. In 2015,
Metuge et al. thoroughly compared the structural differences of the three
enzymatic classes in an attempt to explore the potential inhibitorymechanisms
of plant-derived anti-Onchocerca compounds.65 In this paper, a docking study
postulated the binding pose inside a plant-derived chemical library. Besides
work by Brophy et al.68 who presented a series of β-carbonyl substituted
glutathione conjugates as inhibitors of OvGST2 (Fig. 15), no other attempts
to design inhibitors of these targets are present in the literature. In the case of
Brophy’s work, a series of β-keto SG conjugates were synthesized and assayed
toward OvGST2 achieving low micromolar concentrations and selectivity
that was greater than 10-fold higher than that of human π-GST (Fig. 15).
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s0090 3.3.2 Glutamylcysteine Synthetase
p0185 The tripeptide glutathione (GSH), which plays an important role in the
maintenance of the intracellular thiol redox state and in detoxification pro-
cesses, is intracellularly regulated by glutathione reductase. The first and
rate limiting step in the synthetic pathway is catalyzed by γ-glutamylcysteine
synthetase (γ-GCS) (Fig. 16).
p0190 In a study by L€uersen et al.,69 γ-GCS was partially purified from the filar-
ial parasiteO. volvulus and preliminary steady-state kinetics were performed.
In order to determine its activity, the Ki value of inhibitors of γ-GCS
L-buthionine-S,R-sulfoximine (BSO) and cystamine (Fig. 17) were deter-
mined to be 0.13 and 3.9 μM, respectively. The two inhibitors presented
Kis 54-fold and 5.9-fold lower Ki values for themammalian enzyme, respec-
tively. Furthermore, the cDNA and the O. volvulus γ-GCS gene encode a
polypeptide of 652 amino acids with 50% and 69% sequence identity to the
human and the C. elegans counterparts, respectively. Filarial γ-GCS is pro-
posed as a potential drug target (Fig. 17).
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Fig. 15f0080 The most potent OvGST2 glutathione adduct of the Brophy’s series.
Fig. 16f0085 Glutathione biosynthetic pathway.
Fig. 17f0090 L-Buthionine-S,R-sulfoximine and cystamine.
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s0095 3.3.3 cAMP-Dependent Protein Kinase
p0195 In the search for new drug target candidates and in order to characterize the
molecular events in the signal transduction of O. volvulus, Fischer et al.70
focused on the identification of signaling molecules of this human parasite.
Using cDNA with an open reading frame of 1122 bp, they isolated the reg-
ulatory subunit of the cAMP-dependent protein kinase (Ov-pka-r) of the
pathogenic human nematode O. volvulus. The predicted protein displays
84% homology to the corresponding protein in C. elegans and 71% to the
human homolog. The authors also localized native Ov-PKA-r within the
nervous system and sensory organs of adultO. volvulus worms and of micro-
filariae using rabbit antisera raised against the recombinant protein for immu-
nohistology. As the predominant expression in the nervous system and
sensory organs, and the unique structural features identify thisO. volvulus sig-
nalingmolecule, cAMP-dependent protein kinase (Ov-pka-r) was claimed as
a new and interesting target for drug development.
s0100 3.3.4 Abl-Like Kinases
p0200 As the genomes ofO. volvulus are now available, new drug targets have been
identified. Abl, a tyrosine kinase inhibitor that plays an important role in
cell proliferation and survival, has been suggested as a potential treatment
for a broad range of protozoan infections. O’Connell et al.,71 have therefore
assessed the ability of FDA approved tyrosine kinase inhibitors imatinib,
nilotinib, and dasatinib (Fig. 18) to kill each of the mammalian stages (adults,
L3 larvae, and microfilariae) of the filarial parasite Brugia malayi, the only
human filarial parasite for which each of these lifecycle stages is available
for in vitro testing. The researchers also assessed the universality of this activity
against the other pathogenic filariae (L. loa,Wuchereria bancrofti, andO. volvulus)
and used three-dimensional modeling to understand the interactions between
the tyrosine kinase inhibitors and the filarial Abl-like proteins. For micro-
filariae, median inhibitory concentrations (IC50 values) on day 6 were
6.06 μM for imatinib, 3.72 μM for dasatinib, and 81.35 μM for nilotinib.
For L3 larvae, 11.27, 13.64, and 70.98 μM, respectively, were found. For adult
males, 41.6, 3.87, and 68.22 μM, respectively, were observed, while for adult
females, the values were 42.89, 9.8, and >100 μM, respectively. Three-
dimensional modeling suggests how these tyrosine kinase inhibitors bind
and inhibit filarial protein activity. Given the safety of imatinib in humans,
the authors then reported that plans were underway for pilot clinical trials
to assess its efficacy in patients with filarial infections (Fig. 18).
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s0105 3.3.5 S-Adenosylmethionine Decarboxylase
p0205 The activity of S-adenosylmethionine decarboxylase (AdoMetDC), a key
enzyme in polyamine biosynthesis, is stimulated specifically by putrescine in
many eukaryotes. The AdoMetDC of the filarial parasite O. volvulus, how-
ever, is not only stimulated by putrescine, but also by the naturally occurring
polyamines spermidine and spermine. Ndjonka et al.72 assayed a variety of poly-
amine analogs as competitive inhibitors toward the stimulatory effect that
putrescine has on O. volvulus and, for comparison purposes, on C. elegans
and human AdoMetDC. Such experiments demonstrate that bis(aralkyl)-
and bis(alkyl)-substituted polyamine analogs with a 3-7-3 backbone, besides
other potential impacts on polyamine metabolism, directly affected the cat-
alytic activity of the key enzyme AdoMetDC, whereby the nematode
enzyme was found to be more sensitive than the human enzyme.
s0110 3.3.6 Superoxide Dismutase
p0210 Originally isolated by Tawe et al.,73 the extracellular superoxide dismutase
fromO. volvulus (OvEC-SOD), which was found in the excretory/secretory
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Fig. 18f0095 Imatinib, nilotinib, and dasatinib structures.
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products of adult worms, was the focus of a study by Ajonina-Ekoti et al.74
Using a combination of site-directed mutagenesis and homology in silico
modeling, the authors highlighted the role of Cys-192 in stabilizing the active
site channel.Moreover, the authors provided evidence that SOD is a target of
the immune response during filarial infections in general. Besides the classical
role of superoxide anion reduction in the extracellular space and the control
of the redox state in and around the parasite, OvEC-SOD might also partic-
ipate in the regulation of inflammatory responses, prevent the depletion of
filarial-derived nitric oxide, deal with ROS produced by the iron deposits
in its gut, and improve the ability of the filarial parasite to resist oxidative
injury caused by the host defense.
s0115 3.3.7 Serine Protease Inhibitor
p0215 Ford et al.75 identified, via an analysis of a molting third-stage larvae-expressed
sequence tag dataset, a novel filarial serine protease inhibitor (SPI), named
Ov-SPI-1, from the human parasitic nematodeO. volvulus. Four other mem-
bers of this family were identified in other filariae. These proteins are related to
the low molecular weight SPIs originally isolated from Ascaris suum where
they are believed to protect the parasite from host intestinal proteases.
The two Ov-SPI transcripts are upregulated in the molting larvae and adult
stages of the development of the parasite. The authors suggest that Ov-SPI
proteins play a vital role in nematode molting by controlling the activity of
an endogenous serine protease(s).
s0120 3.3.8 Prolyl 4-Hydrolase
p0220 The cuticle of parasitic nematodes consists primarily of a network of collagen
molecules. Prolyl 4-hydroxylase is the enzyme responsible for collagen mat-
uration and is therefore central in cuticle biosynthesis and a potentially impor-
tant chemotherapeutic target. Merriweather et al.76 characterized and
expressed enzymatically active recombinant filarial prolyl 4-hydroxylase.
The derived amino acid sequence of Ov-phy-1 encoded a peptide that was
very similar to the two C. elegans prolyl 4-hydroxylase homologs and to iso-
form II enzymes of vertebrates. Studies, based on expressed sequence tag
analysis and developmental polymerase chain reactions (PCRs), demonstrated
that Ov-phy-1 was expressed in L3 and adult parasites. At present, besides the
in vitro production of enzymatically active O. volvulus prolyl 4-hydroxylase,
this technique should also facilitate the identification of specific inhibitors of
the parasite enzyme. However, no examples have yet been released.
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s0125 3.3.9 Phosphoglycerate Mutase
p0225 Phosphoglycerate mutase catalyzes the isomerization of 3-phosphoglycerate
and 2-phosphoglycerate in glycolysis and gluconeogenesis. Two distinct
types of PGM exist in nature, one that requires 2,3-bisphosphoglycerate
as a cofactor (dPGM), and another that does not (iPGM), as it is structurally
distinct and possesses different mechanisms of action. Nematodes possess the
iPGM form, whereas mammals have dPGM. Raverdy et al.77 cloned and
expressed iPGM from O. volvulus and described the catalytic properties of
O. volvulus, B. malayi, and C. elegans iPGM enzymes. The high similarity
in catalytic properties shown by the enzymes indicates that a single enzyme
inhibitor would probably be effective against all nematode enzymes, which
supports the development of iPGM as a promising drug target in parasitic
nematodes. In work by Dhamodharan et al.,78 an analysis of partial genomic
and amino acid sequences and the phylogenetic tree of W. bancrofti
(Wb-iPGM), the major causative agent of human lymphatic filariasis, indi-
cated that this gene, apart from being a potential drug target, could also
provide diagnostic, taxonomical, and evolutionary markers. This study is
the first report of the characterization of the iPGM gene from W. bancrofti.
The Wb-iPGM isoform-1 gene encodes an ORF of 515 amino acids and
is found to share 96.0% amino acid sequence identity with the iPGM of
O. volvulus. Serine and all the other 13 amino acid residues involved in
the catalytic function of iPGM are highly conserved. Such similarities make
such enzymes promising drug target in parasitic nematodes.
s0130 3.3.10 Homologous Transcription Factor (SKN-1)
p0230 Choe et al.79 have recently and effectively reviewed the role of the detox-
ification gene regulator, SKN-1, in mediating resistance to anthelmintics in
nematodes. The homologous transcription factor, SKN-1, presents in the
free-living model nematode C. elegans, acts as a master regulator of detox-
ification and antioxidation genes. Despite similar functions, SKN-1 and
NRF2 have important differences in structure and regulatory pathways.
Protein alignment and phylogenetic analyses indicate that these differences
are shared among many nematodes, making SKN-1 a candidate for specif-
ically targeting nematode detoxification and antioxidation.
s0135 3.3.11 Glyoxalase
p0235 Detoxified enzymically by the glyoxalase system, glyoxal, methylglyoxal, and
other physiological α-oxoaldehydes are formed by the lipid peroxidation,
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glycation, and degradation of glycolytic intermediates. Sommer et al.80 inves-
tigated the physiological function of glyoxalase I in parasitic organisms. The
cDNA for glyoxalase I, from the filarial nematode O. volvulus (designated
Ov-GloI), was cloned and characterized. Because of the high degree of
sequence identity (60%) with human glyoxalase I, for which the X-ray struc-
ture is available, it was possible to build a three-dimensional model of
Ov-GloI. Critical differences in the residues that line the hydrophobic
substrate-binding pocket of Ov-GloI are present, as compared to human
glyoxalase I, and should be used as a starting point for the design of inhibitors.
Using semiquantitative PCR enzyme-linked immunosorbent assay (ELISA),
the authors also showed that Ov-GloI is expressed at elevated levels under
conditions of oxidative stress.
s0140 3.3.12 Glyceraldehyde-3-Phosphate Dehydrogenases
p0240 Erttmann et al.81 focused their attention on the glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) protein family in the O. volvulus worm produc-
ing, via the screening and cloning of a cDNA library, a clone of 1650 bp.
A comparison of the complete amino acid sequence identified this protein
as a member of the GAPDH protein family. The recombinantly expressed
protein shows GAPDH enzymatic activity and plasminogen-binding capac-
ity. Using immunohistology, Ov-GAPDH was observed in microfilariae,
infective larvae, and adult male and female worms, in particular in the mus-
culature of the body wall.
s0145 3.3.13 Cathepsin Proteases
p0245 In a study by Lustigman et al.,82 the successful use of RNA interference
(RNAi) to investigate gene function in the third-stage larvae (L3) of human
filarial parasite O. volvulus was proposed. In particular, the authors targeted
two specific gene products,O. volvulus cathepsin L (Ov-CPL) and cathepsin
Z-like (Ov-CPZ) cysteine proteases, which were proposed to function
during O. volvulus L3 molting. This study conclusively validates that both
enzymes are essential for the molting ofO. volvulus L3 to fourth-stage larvae.
s0150 3.3.14 N-Myristoyltransferase
p0250 Myristoylation is a lipid modification involving the addition of a 14-carbon
unsaturated fatty acid, myristic acid, to the N-terminal glycine of a subset
of proteins. This is a modification that promotes their binding to cell mem-
branes for a variety of biological functions. The process is catalyzed by
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N-myristoyltransferase (NMT), an enzyme which has been validated as a
drug target in human cancers, and for infectious diseases caused by fungi,
viruses, and protozoan parasites. Galvin et al.83 purified C. elegans and
B. malayiNMTs as active recombinant proteins and carried out kinetic ana-
lyses with their essential fatty acid donor, myristoyl-CoA, and peptide sub-
strates. The genetic and chemical studies performed in the study highlighted
the importance of myristoylation in the synthesis of functional proteins in
nematodes and have shown, for the first time, that NMT is required for via-
bility in parasitic nematodes. The authors suggested that targeting NMT
could be a valid approach for the development of chemotherapeutic agents
against nematode diseases, including filariasis.
s0155 3.3.15 Onchocerca Decretory Alkaline Phosphatase
p0255 In a study by Cho-Ngwa et al.,84 anOnchocerca secretory alkaline phospha-
tase was detected, purified, and characterized. The enzyme was found to be
secreted by both O. ochengi and O. volvulus worms. It was shown to be of
Onchocerca origin thanks toWestern blotting with bovine onchocerciasis sera
and its time-dependent release in cultures. The enzyme was competitively
inhibited by inorganic phosphate with an apparent inhibition constant (Ki)
of 3.330.04 mM, whereas l-phenylalanine inhibited it in a mixed way
with a Ki of 3.180.03 mM. While contributing to the understanding of
metabolism in Onchocerca, the present, apparently unique, enzyme, which
probably serves in the nutrition of the parasite, could be further character-
ized as a macrofilaricide target or diagnostic marker in onchocerciasis.
s0160 3.3.16 Blisterase
p0260 Blisterase is a subtilisin-like proprotein convertase of nematodes. The
enzyme is named after the blistered cuticle found in C. elegans with the
bli-4 e937 mutation. The critical role of the enzyme in cuticle production
makes it a potential drug target for parasitic nematodes. In a study by Poole
et al.,85 blisterase from the parasitic nematode O. volvulus was cloned and
expressed. The catalytic domain of the protease exhibits 84% identity with
the corresponding domain of its closest homolog, Caenorhabditis elegans
blisterase.O. volvulus blisterase, expressed in insect cells, has maximal activity
in 1 mM calcium at neutral pH. The protease is inhibited by EDTA, the
suicide substrates decanoyl-RVKR-chloromethylketone, α1-antitrypsin
Portland, and by its own propeptide.
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s0165 4. METHODOLOGIES FOR ONCHOCERCIASIS DIAGNOSIS
p0265 Accurate filariasis identification in humans is essential for the implemen-
tation and evaluation of MDA programs to control onchocerciasis. Moreover,
correct identification is important, especially when other live microfilaria in
the skin can produce misidentification and when atypical filarial localizations
occurring in the human host make microscopic diagnosis complicated.86
Determining the infection levels in vector populations is also important
for assessing transmission, deciding when drug treatments may be terminated
and for monitoring recrudescence.
p0270 Will be describe methodologies for onchocerciasis diagnosis below and
pay particular attention of the involvement of new biological assays.
s0170 4.1 Clinical Examination
p0275 Individuals which contract onchocerciasis develop subcutaneous nodules con-
taining the adult worm, predominantly over bony prominences. Microfilariae
are released from these nodules to the skin and ocular tissues. Diagnosis should
bemade by taking skin snips from the back, hips, and thighs and visualizing the
microfilariae of O. volvulus. Eosinophilia and positive serology support the
diagnosis.87 The initial diagnostic methods for determining O. volvulus infec-
tion are: an examination of the skin for signs of onchodermatitis and the detec-
tion of subcutaneous palpable nodules (onchocercomata) by palpation or
ultrasonography. However, these methods are time consuming and require
qualified individuals that can recognize onchocercomata by palpation and
correctly identify the larvae. Although ultrasonography is probably more sen-
sitive than palpation for detecting nodules (especially deeper onchocercomata),
it is impractical for programmatic use as it requires special equipment and
trained personnel.88
s0175 4.2 Microscopic Identification of Microfilariae in Skin Snips
p0280 Skin microfilariae can be identified by microscopic examination of skin
snips. Skin snips (superficial biopsies weighing 1–2 mg) are incubated in
saline for 30 min and then examined for microfilariae. Longer incubation
times increase sensitivity, but decrease the practicality of the method.
Skin snip microscopy is more sensitive in detecting active infections than
clinical examination.Microscopic examination is cheap and easy to perform.
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Nevertheless, skin snip examination is not sensitive in the detection of
early infections or for the diagnosis of individuals with low microfilaria
densities in the skin. Its sensitivity also depends on where skin snips were
taken and the stage of the disease. Furthermore, skin snip practice is incon-
venient, the instruments used to obtain snips are expensive and, as they are
not disposable, particular care must be taken to ensure that blood borne
viruses are not transmitted in field surveys. This method is not beneficial
in determining when to end ivermectin treatment. A fast, inexpensive
and noninvasive diagnostic test, for onchocerciasis, i.e., live adult worms,
has therefore been the subject of study in endemic areas to facilitate elim-
ination programs.
s0180 4.3 Nucleic Acid-Based Molecular Assays
p0285 Several studies have reported improvements in the microscopic examina-
tion of skin snips, such us the detection of parasite DNA in extracts
prepared from skin snips.89 This method is based on the detection and
PCR amplification of anO. volvulus-specific repeated sequence, designated
0–150.89 However, this procedure still entails the collection of a skin
snip. Toe et al.90 demonstrated that the 0–150 PCR assay may be used
to detect O. volvulus DNA even in skin scrapings collected from infected
persons. This assay is not as sensitive as performing the O-l50 assay directly
on skin snips. However, the assay overcomes the disadvantages inherent
in the collection of skin snips and is less invasive. One limitation of the
method is that the existence of a closely related cattle parasite,
O. ochengi, in Africa complicates the use of this test, and an additional
hybridization with a specific O. volvulus DNA probe is required to achieve
specificity. A new species-specific DNA biomarker, encoding O. volvulus
glutathione S-transferase1a (OvGst1a), has been identified that can be used
in PCR without geographic restriction.91
p0290 PCR is an expensive technique for many countries where onchocerciasis
is endemic. For this purpose, loop-mediated isothermal amplification
(LAMP), an alternative technique, has recently been developed.91 LAMP
is a one-step, nucleic acid amplification (NINA) technique that quickly
amplifies, with minimal instruments, a few copies of target DNA to 109 cop-
ies in less than 1 h even when large amounts of nontarget DNA are present.
LAMP is performed under isothermal conditions (64°C) in a simple heat
block or water bath for 80 min. The DNA polymerase is then inactivated,
using a Loopamp Realtime Turbidimeter, under heating at 80°C for 2 min.
Turbidity data were analyzed using the LA-320c software package, and
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a positive reaction was defined as when the change in turbidity over time
reaches a value of 0.1 produced by the precipitation of magnesium pyro-
phosphate (Fig. 19A).92
p0295 For colorimetric LAMP, reactions were carried out at 64°C for 60 min.
Neutral red (NR) or hydroxy naphthol blue (HNB) dyes were employed to
detect amplification. Samples turn pink if positive or yellow if negative using
NR (Fig. 19B). For HNB, samples changed from violet to sky blue when
positive (Fig. 19C). LAMP sensibility is between 1 and 0.00001 ng
(Fig. 19).92
p0300 Poole et al. have described high levels of specificity and sensitivity for var-
ious filarial nematode LAMP assays, including B. malayi, L. loa, O. volvulus,
andW. bancrofti.93 A recent, technological upgrade for LAMP has been pro-
duced that performs the reactions in a portable noninstrumented NINA
device that provides a stable heat source.93
s0185 4.4 Diethylcarbamazine Patch Test
p0305 Diethylcarbamazine was the drug of choice for onchocerciasis therapy for
30 years. However, treatment with diethylcarbamazine provokes side effects
Fig. 19f0100 Sensitivity of O-150 LAMP. Various dilutions ofO. volvulus genomic DNA ranging
from 0.00001 to 1.0 ngwere amplified. (A) LAMP reactions were visualized using turbidity.
(B) Colorimetric dyes, neutral red, and (C) colorimetric dyes, hydroxy naphthol blue.92
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in patients infected withO. volvulus that have been named theMazzotti reac-
tion. These reactions, which occur within a few hours after an oral dose,
include, dermal edema, lymphadenopathy, itching, fever, maculopapular
eruptions, but also more severe manifestations such as meningism, arthrop-
athy, tachycardia, hypotension, severe prostration, and even death.94 The
mechanism of action is thought one of the inflammatory reactions, partic-
ularly involving eosinophils, associated with the exposure and killing of the
microfilariae. In order to limit the severity of these reactions, some studies
evaluated the use of topical application of diethylcarbamazine patch test to
detect early reappearance ofO. volvulus transmission in a community where
control activities have been interrupted. The diethylcarbamazine patch test
indirectly detects microfilariae present in the skin by inducing a localized
Mazzotti reaction.88 Diethylcarbamazine cream, in a gauze material, is
applied to the skin and 1–2 days after patch application, pruritic papules
appear in response to microfilariae death. Multiple patches can be applied
to various sites to reduce the possibility of false-negative reactions and
can be evaluated in 4–8 h. Some patients with loiasis can give false-positive
results, but Ozoh et al.95 demonstrated that this could be useful in areas
where onchocerciasis is coendemic with loiasis. The test is inexpensive
and quick for survey work and clinical diagnosis. Finally, the reaction is
localized and causes the patient only limited itching.94
p0310 A ready-to-use diethylcarbamazine containing patch, called the LTS-2
patch, has recently been developed, and Awadzi et al.96 have demonstrated
that its safety, tolerability, and ability to detect infections are comparable to
those of the diethylcarbamazine patch.96
s0190 4.5 Antibody Diagnostic Tests
p0315 Alternative methods, which are based on the detection of antibodies or anti-
gens in body fluids, have been developed to improve upon the diagnoses of
onchocerciasis. Antibody-based diagnostic tests for onchocerciasis are
potentially useful as tools for identifying early infections, and also for mon-
itoring the efficacy of control programs. IgG4 antibodies are generally absent
in healthy child and adult serum. Some studies have reported an evident
IgG4 antibody response in patients with onchocerciasis.Weil et al. evaluated
total IgG and IgG4 antibodies toO. volvulus adult antigen (OvAg), in serum
from patients withO. volvulus infections, using an enzyme immune assay and
immunoblot analysis.97 IgG4 antibodies were detected by enzyme immuno-
assay in onchocerciasis serum samples, but cross-reactive IgG4 antibodies
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were present in serum pools from patients infected with other filariae. These
results confirm the specificity of IgG4 antibody assays against the IgG anti-
body for filariasis and extend the observation to include onchocerciasis, but
cross-reactivity among filariae limits the utility of this approach. However,
another limitation of this approach is that IgG4 antibodies develop relatively
slowly in children. Moreover, antibody detection does not distinguish
between active and past infections.
p0320 Chandrashekar et al. used measurements of antibodies in humans for the
detection of filarial antigens in immuno-ELISA assays in 1996.98 This anti-
body assay is based on recombinant O. volvulus antigens encoded by cDNA
clones, OC 3.6 andOC 9.3, which are sensitive and specific for the diagnosis
of onchocerciasis in human serum from patients that also present other dis-
eases, such as lymphatic filariasis, loiasis, dracunculiasis, and schistosomiasis, that
are unreactive with these antigens. OC 3.6 encodes an O. volvulus antigen
that is similar to the protein product of Ov33which is believed to be a pepsin
inhibitor. OC 9.3 encodes a 15 kDa native antigen, which it is closely
related to OV7 that encodes an O. volvulus cystatin. Previous studies have
shown that these proteins are present in the developing larvae and adult
worms of O. volvulus and that the antibodies to these antigens can develop
long before the onset of microfilariae patency. Antibody detection does not
distinguish between active and past infections.98
p0325 Bradley et al. developed an ELISA, in 1998, that is able to detect specific
O. volvulus antibodies using a “diagnostic cocktail” of three recombinant anti-
gens, Ov10, Ov11, and Ov29.99 Ov10 is found in the larval adult stages (L3
and L4) of the worm, while the other two antigens are known to be present
in adult female worms.99 The cocktail showed 96% sensitivity and 100%
specificity with sera from microfilariae-positive patients compared with
99% sensitivity and only 59% specificity when using a crude O. volvulus
extracted based assay.99 Nde et al.100 developed recombinant hybrid pro-
teins OvH2 and OvH3. The first OvH2 is composed of Ov20 fused to
Ov33, and OvH3 consists of the C-terminus of Ov20 linked to Ov33.
Ov20 is a secreted glycoprotein found in the body wall of adult female
O. volvulus. OvH2 has been shown to have a sensitivity of 98.5% and a spec-
ificity of 97.7%, and OvH3 has been shown to have a sensitivity of 98.5%
and a specificity of 95.4%, when tested on sera from 132 microfilariae-
positive patients.101
p0330 The two antigens found in OvH3, Ov20 and Ov33, are also found in
infective larvae and microfilariae, meaning that it is possible that the assay is
measuring antibody responses to the early stages of the parasite. This indicates
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that the assaymay have a role to play in the diagnosis of low level and prepatent
infections as well as in established infections. The assay may also be valuable in
assessing the level of exposure to O. volvulus within a community.101
p0335 The most developed and advanced serological marker for onchocerciasis
exposure is the IgG4 response to theO. volvulusmarker Ov16 antigen that is
expressed by the larval stages (L3 and L4) of the parasite.102
p0340 Ov16 IgG4 antibody response is also an accurate marker for active infec-
tion in children under 11 years of age. In America, the immunological assay
that measures anti-Ov16 IgG4 seroconversion using a ELISA in children has
been used widely to demonstrate that transmission has been interrupted. In
Africa, the anti-Ov16 marker is increasingly used to confirm the interrup-
tion of transmission in foci that receive extensive rounds of MDA.
p0345 A new rapid diagnostic test (RDT) for the detection of IgG4 against Ov16
has been developed as a practical, convenient, and standardized alternative for
use in the field (SD BIOLINE Onchocerciasis IgG4 Rapid Test).103
s0195 5. CONCLUSIONS
p0350 We have herein conducted a literature search with the purpose of
shedding some light onto the drug design scenario in onchocerciasis;
a neglected tropical disease that has a pressing need for a therapeutic revolution.
Despite the existence of a safe drug that can be used for mass treatment, iver-
mectin, the emergence of ivermectin resistance strengthens the crucial need
to identify new drug targets and agents that can effectively treat this disease.
Only a few examples of drug design programs directed toward the discovery
and design of newmolecules for use as possible drug candidates have been seen
over the last 18 years. However, knowledge of the biology and physiology
of the causative agent, O. volvulus filarial nematode, has been enriched, over
these years, by linking a variety of enzymes to specific roles in the life of the
parasite, both as microfilariae and the adult worm. It is possible, that such dis-
coveries could lead to the discovery of drug targets and drug candidates for
future onchocerciasis treatment.
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Non-Print Items
Abstract
Onchocerciasis, also called river blindness, is a neglected tropical disease which is in des-
perate need of a therapeutic revolution. This debilitating disease, endemic in
31 countries in sub-Saharan Africa, Yemen, and Latin America, is a leading cause
of blindness in the developing world. The infection is caused by the filarial parasitic
nematodeOnchocerca volvulus that is transmitted to humans by the black fly Simulium
spp. Its pathology, whose symptoms are onchodermatitis, musculoskeletal pain, and
various stages of blindness, is a result of the death of the microfilariae in the skin and
eyes. This review covers the drug design and early detection fields of this pathology
and pays particular attention to the period after the introduction of ivermectin, which
is the only drug available for mass treatment. The emergence of ivermectin resis-
tance justifies the crucial need to identify new drug targets and agents that can effec-
tively treat onchocerciasis.
Keywords: Neglected tropical diseases, Onchocerciasis, Onchocerca volvulus, Iver-
mectin, Chitinase, Scaffold hopping
Comp. by: S.Rajaram Stage: Revises1 Chapter No.: 1 Title Name: ARMC
Date:24/9/18 Time:07:47:34 Page Number: 39
ARTICLE IN PRESS
To protect the rights of the author(s) and publisher we inform you that this PDF is an uncorrected proof for internal business use only by the author(s),
editor(s), reviewer(s), Elsevier and typesetter SPi. It is not allowed to publish this proof online or in print. This proof copy is the copyright property of
the publisher and is confidential until formal publication.
These proofs may contain colour figures. Those figures may print black and white in the final printed book if a colour print product
has not been planned. The colour figures will appear in colour in all electronic versions of this book.
